Patents by Inventor Mitsujiro Osawa

Mitsujiro Osawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240052309
    Abstract: [Problems] To provide a method for producing regenerated T cells via iPS cells into which TCRs isolated from tumor tissue-infiltrating CD106-positive T cells have been introduced. [Solutions] Provided is a method for producing regenerated T cells via iPS cells, comprising: 1. A step for preparing cDNAs respectively encoding a TCR ? chain and a TCR ? chain from individual cells in a CD106-positive T cell population obtained from subjects and having reactivity with a tumor-related antigen; 2. A step for reprogramming peripheral blood mononuclear cells which are obtained from the subjects and from which B cells and T cells have been removed or T cells into iPS cells, and selecting iPS cell clones having high efficiency of differentiation into T cells from the obtained iPS cells; 3.
    Type: Application
    Filed: December 29, 2021
    Publication date: February 15, 2024
    Inventors: Shin Kaneko, Ryosuke Gonotsubo, Mitsujiro Osawa, Yasumichi Hitoshi, Kazuo Yamashita, Nicolas Claude Paul Sax
  • Publication number: 20230183645
    Abstract: [Problem] To provide a method for producing regenerated T cells by introducing antigen-specific T cell receptors to iPS cell clones or hematopoietic stem cells differentiated from iPS cell clones, immature T cells or mature T cells.
    Type: Application
    Filed: September 17, 2021
    Publication date: June 15, 2023
    Inventors: Shin Kaneko, Kyosuke Gonotsubo, Mitsujiro Osawa, Yasumichi Hitoshi
  • Publication number: 20050221477
    Abstract: The sustaining stem cells for example, hematopoietic stem cells while holding in the undifferentiated state and maintaining pluripotency by providing a polypeptide having a WIF domain for example, WIF-1 to the stem cells has been successfully achieved. This polypeptide preferably also contains an EGF-like repeat. This result has been achieved by providing a polypeptide preferably having the WIF domain together with a stem cell survival factor such as SCF. Thus, it becomes possible to easily provide a large amount of stem cells for example, hematopoietic stem cells containing functional precursor cells. It has also become possible to more efficiently transfer a gene into the stem cells. Because it is homogeneous and almost free from impurities, the stem cell composition can remarkably relieve side effects for example, infection, which occur in conventional therapies using hematopoietic stem cells.
    Type: Application
    Filed: March 11, 2002
    Publication date: October 6, 2005
    Applicant: REPROCELL, INC
    Inventors: Hideo Ema, Hiromitsu Nakauchi, Mitsujiro Osawa